UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 21,601 Shares of Medpace Holdings, Inc. $MEDP

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 15.3% during the second quarter, according to its most recent filing with the SEC. The fund owned 119,206 shares of the company’s stock after selling 21,601 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Medpace were worth $63,130,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in MEDP. BlackRock Inc. bought a new stake in Medpace in the second quarter worth about $1,323,047,000. AQR Capital Management LLC grew its position in shares of Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after acquiring an additional 404,226 shares during the period. Madison Asset Management LLC purchased a new stake in shares of Medpace during the 2nd quarter worth approximately $128,956,000. Bank of America Corp DE bought a new stake in shares of Medpace in the 2nd quarter worth approximately $116,891,000. Finally, Arrowstreet Capital Limited Partnership raised its holdings in shares of Medpace by 205.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after purchasing an additional 211,411 shares during the period. Institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

MEDP has been the subject of several research reports. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and increased their price target for the stock from $490.00 to $515.00 in a research note on Tuesday, July 7th. Weiss Ratings upgraded Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. Truist Financial upped their price objective on shares of Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a report on Friday, July 24th. Finally, BMO Capital Markets lifted their target price on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research note on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $595.20.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $593.02 on Thursday. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The stock has a market cap of $16.55 billion, a PE ratio of 34.76, a price-to-earnings-growth ratio of 2.60 and a beta of 1.15. The stock has a fifty day moving average of $571.91 and a 200-day moving average of $497.71.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same quarter in the previous year, the firm earned $3.10 EPS. The company’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Insider Activity

In related news, VP Susan E. Burwig sold 7,500 shares of the stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total value of $4,500,000.00. Following the sale, the vice president owned 62,984 shares in the company, valued at approximately $37,790,400. This trade represents a 10.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Fred B. Davenport, Jr. sold 7,283 shares of Medpace stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total value of $4,414,590.45. Following the sale, the director directly owned 3,798 shares of the company’s stock, valued at $2,302,157.70. This represents a 65.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 134,471 shares of company stock valued at $82,151,311 in the last quarter. 20.50% of the stock is currently owned by company insiders.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.